Giant atrial septal aneurysm simulating a right atrial tumour

In the past 10 years, an enormous amount of research has focused on the role of NAD(P)H oxidases in cardiovascular physiology and pathophysiology. Initially, investigators characterised these enzyme activities biochemically and functionally, but more recently, the molecular identification of a family of Nox (NADPH oxidase) proteins related to the respiratory burst NAD(P)H oxidase of neutrophils has led to an explosion of information about expression patterns, regulation, and functional significance of these enzyme complexes. Nox enzymes have been found to be involved in the regulation of vascular tone, smooth muscle growth, inflammatory responses, and matrix metalloproteinase activity. They have been implicated in hypertension, atherosclerosis, heart failure, diabetic vascular disease, and restenosis. In this article, the current status of the molecular basis for and the functional consequences of activation of these novel enzymes will be discussed. The first Nox enzyme to be cloned and characterised was termed gp91phox (or Nox2), because it is the catalytic unit of the phagocytic respiratory burst oxidase, which is important for non-specific host defence against invading microbes. This protein exists in a macromolecular complex with p22phox, another membrane subunit that stabilises gp91phox and interacts with the cytosolic regulatory factor p47phox. p47phox has two tandem SH3 groups that interact with auto-inhibitory domains to maintain the protein in an inactive state. Upon phosphorylation of p47phox by protein kinase C, this interaction is lost, and the SH3 groups and proline-rich tail are exposed and bind to the membrane subunits and a second regulatory cytosolic subunit, p67phox. p67phox, in turn, serves as a binding site for the small molecular weight G protein Rac, which modulates enzyme activity.1 Originally, gp91phox was thought to be restricted to phagocytic cells. Recent work, however, indicates that gp91phox is expressed at low, but functionally important levels in many tissues. More importantly, in …

[1]  K. Griendling,et al.  Distinct Subcellular Localizations of Nox1 and Nox4 in Vascular Smooth Muscle Cells , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[2]  Don P Giddens,et al.  Role of xanthine oxidoreductase and NAD(P)H oxidase in endothelial superoxide production in response to oscillatory shear stress. , 2003, American journal of physiology. Heart and circulatory physiology.

[3]  R. Clempus,et al.  Vascular NAD(P)H oxidases: specific features, expression, and regulation. , 2003, American journal of physiology. Regulatory, integrative and comparative physiology.

[4]  M. Kohjima,et al.  Novel Human Homologues of p47phox and p67phox Participate in Activation of Superoxide-producing NADPH Oxidases* , 2003, Journal of Biological Chemistry.

[5]  M. Jankowski,et al.  NAD(P)H Oxidase Mediates Angiotensin II–Induced Vascular Macrophage Infiltration and Medial Hypertrophy , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[6]  Steven M Holland,et al.  Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. , 2003, The Journal of clinical investigation.

[7]  K. Krause,et al.  Two Novel Proteins Activate Superoxide Generation by the NADPH Oxidase NOX1* , 2003, The Journal of Biological Chemistry.

[8]  F. Rey,et al.  The Reactive Adventitia: Fibroblast Oxidase in Vascular Function , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[9]  N. Kalinina,et al.  Cytochrome b558—Dependent NAD(P)H Oxidase—Phox Units in Smooth Muscle and Macrophages of Atherosclerotic Lesions , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[10]  Hua Cai,et al.  Role of p47phox in Vascular Oxidative Stress and Hypertension Caused by Angiotensin II , 2002, Hypertension.

[11]  A. Shah,et al.  Activation of NADPH Oxidase During Progression of Cardiac Hypertrophy to Failure , 2002, Hypertension.

[12]  A. Shah,et al.  Intracellular Localization and Preassembly of the NADPH Oxidase Complex in Cultured Endothelial Cells* , 2002, The Journal of Biological Chemistry.

[13]  W. R. Taylor,et al.  Superoxide Production and Expression of Nox Family Proteins in Human Atherosclerosis , 2002, Circulation.

[14]  Z. Galis,et al.  This Review Is Part of a Thematic Series on Matrix Metalloproteinases, Which Includes the following Articles: Matrix Metalloproteinase Inhibition after Myocardial Infarction: a New Approach to Prevent Heart Failure? Matrix Metalloproteinases in Vascular Remodeling and Atherogenesis: the Good, the Ba , 2022 .

[15]  A. Shah,et al.  Pivotal Role of a gp91phox-Containing NADPH Oxidase in Angiotensin II-Induced Cardiac Hypertrophy in Mice , 2002, Circulation.

[16]  J. Wilcox,et al.  Upregulation of Nox‐Based NAD(P)H Oxidases in Restenosis After Carotid Injury , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[17]  S. Holland,et al.  p47phox is required for atherosclerotic lesion progression in ApoE(-/-) mice. , 2001, The Journal of clinical investigation.

[18]  D. Sorescu,et al.  Novel gp91phox Homologues in Vascular Smooth Muscle Cells: nox1 Mediates Angiotensin II-Induced Superoxide Formation and Redox-Sensitive Signaling Pathways , 2001, Circulation research.

[19]  D. Sorescu,et al.  Modulation of Protein Kinase Activity and Gene Expression by Reactive Oxygen Species and Their Role in Vascular Physiology and Pathophysiology , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[20]  P. Várnai,et al.  Identification of renox, an NAD(P)H oxidase in kidney. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[21]  A. Chait,et al.  Impaired superoxide production due to a deficiency in phagocyte NADPH oxidase fails to inhibit atherosclerosis in mice. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[22]  Y. Suh,et al.  Cell transformation by the superoxide-generating oxidase Mox1 , 1999, Nature.

[23]  B. Babior NADPH oxidase: an update. , 1999, Blood.